Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Aquestive Therapeutics Inc (AQST)

Aquestive Therapeutics Inc (AQST)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 61,791
  • Shares Outstanding, K 33,582
  • Annual Sales, $ 52,610 K
  • Annual Income, $ -66,250 K
  • 60-Month Beta 2.46
  • Price/Sales 1.20
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -0.52
  • Number of Estimates 2
  • High Estimate -0.49
  • Low Estimate -0.54
  • Prior Year -0.59
  • Growth Rate Est. (year over year) +11.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.41 +49.65%
on 03/16/20
3.63 -41.95%
on 03/09/20
-1.71 (-44.76%)
since 03/06/20
3-Month
1.41 +49.65%
on 03/16/20
6.96 -69.68%
on 01/07/20
-3.73 (-63.87%)
since 01/06/20
52-Week
1.41 +49.65%
on 03/16/20
10.00 -78.90%
on 12/02/19
-4.44 (-67.79%)
since 04/05/19

Most Recent Stories

More News
Memgen Appoints Gregory Brown as Chief Executive Officer

Houston, Texas--(Newsfile Corp. - March 17, 2020) - ​Memgen, a private biotechnology company developing innovative immuno-oncology drugs, announced today that its Board of Directors has appointed Gregory...

AQST : 2.11 (+14.67%)
CLBS : 1.8100 (+2.84%)
Company News for Mar 13, 2020

Companies In The News Are: POAI, APT, AQST, TACO

APT : 14.96 (-5.44%)
TACO : 3.26 (+3.82%)
AQST : 2.11 (+14.67%)
POAI : 1.3900 (+6.11%)
Aquestive Therapeutics (AQST) Reports Q4 Loss, Tops Revenue Estimates

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -6.67% and 4.08%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?...

AQST : 2.11 (+14.67%)
Aquestive Therapeutics: 4Q Earnings Snapshot

WARREN, N.J. (AP) _ Aquestive Therapeutics Inc. (AQST) on Wednesday reported a loss of $12.6 million in its fourth quarter.

AQST : 2.11 (+14.67%)
Will Aquestive Therapeutics (AQST) Report Negative Earnings Next Week? What You Should Know

Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AQST : 2.11 (+14.67%)
Top Ranked Momentum Stocks to Buy for December 9th

Top Ranked Momentum Stocks to Buy for December 9th

IDN : 2.82 (+33.65%)
GRBK : 6.97 (+12.06%)
AVDL : 8.78 (+10.03%)
AQST : 2.11 (+14.67%)
Company News For Nov 26, 2019

Companies In The News Are:

ICPT : 62.85 (+6.98%)
CBAY : 1.4900 (+4.93%)
SURF : 1.7400 (+4.19%)
AQST : 2.11 (+14.67%)
Healthcare Drives Wall Street: 5 Soaring ETFs & Stocks

Decent fundamentals and valuations as well as encouraging developments put these medical ETFs and stocks in focus.

PTH : 86.87 (+4.32%)
PBE : 47.87 (+5.97%)
XBI : 80.40 (+7.40%)
CNCR : 20.23 (+4.11%)
DXCM : 269.31 (+3.28%)
CLVS : 6.80 (+11.48%)
BIIB : 311.39 (+3.62%)
PTI : 1.1600 (+2.65%)
AQST : 2.11 (+14.67%)
FTSV : 95.51 (+0.05%)
ARKG : 31.79 (+6.71%)
All You Need to Know About Aquestive Therapeutics (AQST) Rating Upgrade to Buy

Aquestive Therapeutics (AQST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

AQST : 2.11 (+14.67%)
Company News for Nov 7, 2019

Companies In The News Are: WW, VNTR, PLT, AQST

PLT : 9.86 (+13.73%)
VNTR : 1.4800 (+6.47%)
WW : 17.13 (+18.06%)
AQST : 2.11 (+14.67%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Trade AQST with:

Business Summary

Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. It commercializes medicines to solve critical health care problems as well as engages on late-stage proprietary product pipeline which focuses on the treatment of diseases of central nervous system. Aquestive Therapeutics, Inc. is based...

See More

Key Turning Points

2nd Resistance Point 2.34
1st Resistance Point 2.23
Last Price 2.11
1st Support Level 1.95
2nd Support Level 1.78

See More

52-Week High 10.00
Fibonacci 61.8% 6.72
Fibonacci 50% 5.70
Fibonacci 38.2% 4.69
Last Price 2.11
52-Week Low 1.41

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar